Effect | Diseases treated | Dosage and Duration Of P. niruri | Description | Reference |
Immuno modulatory effect (Randomized Clinical trials) | Tuberculosis (n = 120 patients) | Oral 50 mg/ml 2 - 6 months | In one study involving 40 active TB patients, a significant elevation of plasma IFN-γ level (+7.65 pg/mL from the mean baseline level of 5.24 pg/mL) was found after 2 months of concomitant treatment. IFN-γ level is critically required to protect the body from and to combat M. tuberculosis | [12] |
Vaginal candidiasis (n = 20 patients) | Oral 100 mg/ml 1 - 3 months | Elevation of IFN-γ level indicates an augmented activity of the T-helper 1 cellular immune response, with concurrent suppression of IL-4 and IL-10 secretion by Th2 subsets, and activation of the macrophages necessary for candida eradication from the vaginal tissues | [13] | |
Toxic modulatory effect | Urolithiasis (n = 150 patients) | Oral 2 g/once Daily For 180 days | complete stone clearance (stone-free condition with residual fragments less than 3 mm) occurred in 93.5% of patients in the treated group. | [14] |
Anti-viral effect | Hepatitis B (n = 140 patients) | Capsule 3 months and 2 year follow up | Recovery index of HBV-DNA, HBeAg is 88.2% and 52.5% respectively. Also, when treatment was stopped recurrence rate were 10.4% and 13.4% respectively. | [15] |
Anti-inflammatory activity | Tonsillo pharyngitis | Capsule 360 mg/3times daily for 7 days | Indicated by the visual analogue scale reduction in swallowing pain and swallowing difficulty within 6 hours after administration. | [15] |